Amanda F. Austin

Counsel

austin-amanda-f
  • JD, Harvard Law School, 2005
  • AB (Government), cum laude, Harvard University, 2002

Qualifications

  • Massachusetts, 2005

Amanda F. Austin

Counsel

Amanda Austin joined Ropes & Gray in 2005 and practices in the life sciences group. Amanda’s practice primarily focuses on the representation of pharmaceutical, medical device and biotechnology companies and non-profit institutions in intellectual property transactions, including licenses, research and development collaboration agreements, strategic commercial partnerships, joint ventures, co-promotion agreements and distribution and manufacturing arrangements.

Experience

  • Represented Pfizer in its contribution of assets related to allogeneic chimeric antigen receptor T cell (CAR-T) therapy to Allogene Therapeutics.
  • Represented a public university in the sale of a portion of its royalty interest in an orphan drug.
  • Assisted multiple clients, including a non-profit institution and a leading pharmaceutical company, with the development of licensing templates for internal use.
  • Represented Ironwood Pharmaceuticals in its licensing agreement with AstraZeneca for the U.S. rights to Zurampic, an FDA-approved treatment for hyberuricemia associated with uncontrolled gout.
  • Represented Beam Therapeutics in connection with its licenses from Editas Medicine and The Broad Institute.
  • Represented Pfizer in its option to acquire AM-Pharma, a private company focused on the development of recombinant human Alkaline Phosphatase (recAP) for the treatment of inflammatory diseases.
  • Represented Hutchison MediPharma in a joint venture with Nestle Health Science to research, develop, manufacture and market nutritional products derived from botanical plant origins.
  • Represented a leading global biotechnology company in a $300 million joint venture to develop and market biosimilars with a Korea-based company.
  • Represented FORMA Therapeutics, Inc. in a drug discovery collaboration with Janssen Pharmaceuticals, Inc. under which FORMA and Janssen agreed to collaborate on drug discovery efforts.
  • Represented Acceleron Pharma, Inc. in a joint development and commercialization agreement with Celgene Corporation for a protein therapeutic. 
  • JD, Harvard Law School, 2005
  • AB (Government), cum laude, Harvard University, 2002
Cookie Settings